This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MiMedx Scientific Study To Be Published In The International Wound Journal

MARIETTA, Ga., July 31, 2013 /PRNewswire/ --  MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been accepted for publication in the International Wound Journal.  The electronic publication of the study will be available in early August, and the hard copy is expected to be published in the December 2013 edition of the International Wound Journal.

To better understand the mechanisms responsible for the healing qualities of MiMedx dehydrated amnion/chorion membrane allografts (dHACM), the MiMedx research department, led by its Chief Scientific Officer, Thomas Koob, PhD, partnered with researchers from Stanford University School of Medicine and The Georgia Institute of Technology Biotechnology Complex.  Parker H. "Pete" Petit, Chairman and CEO, said, "Fundamentally, the researchers proved, among other things, that our allografts attract critically important regenerative stem cells to the wound site to help repair the wound. In effect, the research confirms that our proprietary PURION® processed allografts act as a "stem cell magnet." 

Bill Taylor, President and Chief Operating Officer, stated, "The research concluded that the MiMedx dHACM allografts positively affect at least four distinct physiological processes critical to wound healing, particularly in chronic wounds. dHACM modulates the inflammatory process, inhibits metalloproteinase activity and matrix degradation, induces regenerative cell proliferation and recruits stem cells. Clearly, multiple factors work in unison to have this kind of impact.  As opposed to a single therapeutic agent, dHACM allografts are a multifaceted, regenerative biomaterial that revitalizes wound healing."

"We will be submitting additional papers that delve deeper into the biological process of our 'stem cell magnet' allografts. These studies involve determining the source of the stem cells, establishing the angiogenic properties of dHACM, and gaining an in depth understanding of various mechanisms of action in wound healing," concluded Petit.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs